Our hypothesis is that ninjurin2 could also be implicated in the transmigration of immune cells during inflammatory processes in MS, affecting in turn the disease activity and explaining the observed relationship between NINJ2 genetic variants, gene expression and MS relapses, as suggested by previous pharmacogenetic studies. The gene discussed is NINJ2; the disease is myeloid sarcoma.